Parkinson's Disease Flashcards
Features of Parkinson’s Disease
Parkinson's: resting tremor rigidity bradykinesia postural instability hypomimia (masked face) hypophonia (soft speech) depression
Pathology of Parkinson’s Disease
Dopamine deficiency or acetylcholine excess
What are the pharmacologic treatment options for PD?
Dopamine precursors Dopamine agonists MAOI inhibitors COMT inhibitors Muscarininc antagonists Amantadine
What 2 enzymes decrease the metabolism of dopamine in the brain (aka raise the level of dopamine)?
MAOI inhibitors and COMT
When should treatment for Parkinson’s be initiated?
when the disease begins to interfere w/activities of daily living, employment, or quality of life
MOA of Amantadine
enhances dopamine release
Blocks glutamatergic NMDA receptors
Why is Rasagiline (MAOI inhibitor) the 1st line tx?
- over Levodopa bc of Levo’s ADE’s
- pts w/ mild to moderate sxs, <65yo, start early
ADE’s of Rasagiline (MAOI inhibitor)
nausea orthostatic hypotension confusion insomnia hallucinations
Rasagiline (MAOI inhibitor) drug interactions
Serotonin syndrome w/ Meperidine (BP changes, tachycardia, N/V, tremor, agitation)
When is Amantadine most useful?
in treating younger patients w/early or mild PD and perhaps later when dyskinesia becomes problematic
Amantindine works well for which specific sxs?
tremor
rigidity
bradykinesia
ADE’s of Amantidine
confusion
dizziness
dry mouth
hallucinations
(similar to anticholinergics)
MOA of Dopamine agonists (Pramipexole)
stimulates dopamine activity on the nerves in the substantia nigra and striatum
ADE’s of Dopamine agonists
*postural hypotension
*impulsive behaviors
pulmonary fibrosis
confusion, hallucinations, sedation, vivid dreaming
Dopamine precursor MOA
replace dopamine once broken down by DOPA-D
Levodopa
Why is Carbidopa added to Levodopa?
carbidopa prevents breakdown of L-Dopa into dopamine in the body therefore preserves more for the brain and lessens body ADE’s
(aka incr. fraction of dose that reaches brain)
Drug interactions b/t Levodopa/Carbidopa
COMT and MAO type B inhibitors diminish doses and prolongs action
ADE’s of Levodopa/carbidopa
drowsiness
dyskinesias (motor complications)
Possible initial treatment for end-of-dose “wearing off” (motor fluctuation)
Increase frequency of carbidopa/L-dopa doses
Add either COMT inhibitor or MAO-B inhibitor or dopamine agonist
Possible initial treatment for “delayed on” or “no on” response
Give carbidopa/levodopa on empty stomach
Use carbidopa/levodopa orally dissolved tablet (avoid controlled release)
Use apomorphine subcutaneous
Possible initial treatment for start hesitation or “freezing”
Increase carbidopa/levodopa dose
Add a dopamine agonist or MAO-B inhibitor
Use PT, assistive walking device, sensory cues
Possible initial treatment for Peak-dose dyskinesia
Provide smaller doses of carbidoopa/L-dopa
Add amantadine
MOA for COMT inhibitors
- blocks conversion of L-Dopa into 3-OMD & prevents conversion of Dopamine to 3-MT
- provides greater percentage of L-dopa to cross the blood brain barrier
What are 2 available COMT inhibitors?
Entacapone
Tolcapone